公开(公告)号：US20250002855A1

公开(公告)日：2025-01-02

申请号：US18886331

申请日：2024-09-16

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Ali MOHAMED ,  Steffen WALTER ,  Yannick BULLIARD

IPC: C12N5/0783 ,  A61K39/00 ,  C07K14/725

Abstract: An in vitro method of expanding γδ T cells includes isolating γδ T cells from a blood sample of a human subject, activating the isolated γδ T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated γδ T cells, and optionally restimulating the expanded γδ T cells.

公开(公告)号：US11690872B2

公开(公告)日：2023-07-04

申请号：US16200308

申请日：2018-11-26

Applicant: Immatics US, Inc.

Inventor： Monique Dao ,  Steffen Walter ,  Melinda Mata ,  Aleksandra Nowicka ,  Yannick Bulliard ,  Sarah Missell ,  Sabrina Kuttruff-Coqui ,  Norbert Hilf

IPC: A61K35/17 ,  C12N5/0783 ,  A61K31/663 ,  A61K31/675 ,  A61K38/20 ,  C07K14/54 ,  C07K14/55 ,  C12N5/00 ,  C12N15/62 ,  C12N15/85 ,  A61K35/12 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/2013 ,  C07K14/5443 ,  C07K14/55 ,  C12N5/0018 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/62 ,  C12N15/8509 ,  A61K2035/122 ,  A61K2035/124 ,  C07K16/2809 ,  C12N2501/155 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2740/10043

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

公开(公告)号：US20210285011A1

公开(公告)日：2021-09-16

申请号：US17197927

申请日：2021-03-10

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  C12N15/10 ,  C07K14/725 ,  C12N15/113

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20210002610A1

公开(公告)日：2021-01-07

申请号：US16893246

申请日：2020-06-04

Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

Inventor： Amir ALPERT ,  Dominik MAURER ,  Anastasiya SMITH ,  Claudia WAGNER ,  Ali MOHAMED

IPC: C12N5/0783 ,  A61K31/5383 ,  A61K31/437

Abstract: Described herein are methods for preparing T cells, including isolating CD8+ T cells from a blood sample obtained from a patient or a donor, culturing the isolated CD8+ T cells in the presence of at least one cytokine, contacting the cultured CD8+ T cells with a multimer containing a target peptide in a complex with an MHC molecule and with at least one binding agent that binds to a T cell surface molecule, in which the multimer is labelled with a first detectable agent and the binding agent is labelled with a second detectable agent, sorting the contacted CD8+ T cells to collect the sorted CD8+ T cells that are detected positive for the first and the second detectable agents, and expanding the collected CD8+ T cells.

公开(公告)号：US20200297768A1

公开(公告)日：2020-09-24

申请号：US16823987

申请日：2020-03-19

Applicant: IMMATICS US, INC.

Inventor： Amir ALPERT ,  Mamta KALRA

IPC: A61K35/17 ,  A61P35/00 ,  C12N15/86 ,  C12N5/0783

Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.

公开(公告)号：US20250034588A1

公开(公告)日：2025-01-30

申请号：US18897063

申请日：2024-09-26

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Agathe BOURGOGNE ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N15/85 ,  A61K39/00 ,  A61P35/00 ,  C12N5/10 ,  C12N7/00 ,  C12N15/86

Abstract: The present disclosure relates to T cells transduced with a viral vector at a volumetric concentration for immunotherapy and methods thereof. In another aspect, the present disclosure relates to the assessment of optimal lentiviral vector concentrations for transducing T cells. The present disclosure further provides for T cell populations produced by methods described herein.

公开(公告)号：US11975025B2

公开(公告)日：2024-05-07

申请号：US16884804

申请日：2020-05-27

Applicant: Immatics US, Inc.

Inventor： Melinda Mata ,  Yannick Bulliard ,  Mamta Kalra

IPC: A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C12N5/078 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/64 ,  C12N15/86

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C12N5/0634 ,  C12N15/64 ,  C12N15/86 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2740/16043

Abstract: A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.

公开(公告)号：US20230348548A1

公开(公告)日：2023-11-02

申请号：US18309080

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Justin GUNESCH ,  Mohammad HOSSAIN ,  Gagan BAJWA ,  Melinda MATA ,  Mamta KALRA

IPC: C12N5/0783 ,  C12N15/86 ,  C07K14/705 ,  C07K16/00 ,  C07K14/54 ,  C07K14/725 ,  A61K39/00 ,  A61K39/39

CPC classification number: C07K14/5443 ,  A61K39/39 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4621 ,  A61K39/4632 ,  A61K39/4633 ,  A61K39/4635 ,  A61K39/4643 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55588 ,  C12N2502/1121 ,  C12N2740/15043

Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.

公开(公告)号：US20230192886A1

公开(公告)日：2023-06-22

申请号：US18053705

申请日：2022-11-08

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Harpreet SINGH ,  Toni WEINSCHENK ,  Steffen WALTER

IPC: C07K16/30 ,  A61K38/17 ,  A61P35/00

CPC classification number: C07K16/3053 ,  A61K38/1774 ,  A61P35/00

Abstract: A method of treating a patient who has a recurrent cancer that presents a peptide, including administering to the patient a treatment composition comprising an antigen binding molecule that binds to the peptide, in which the patient has received a prior treatment with a pretreatment composition comprising a second antigen binding molecule that binds to a different peptide.

公开(公告)号：US20220202862A1

公开(公告)日：2022-06-30

申请号：US17563599

申请日：2021-12-28

Applicant: Immatics US, Inc.

Inventor： Gagan BAJWA ,  Mamta KALRA ,  Melinda MATA

IPC: A61K35/17 ,  C12N15/86 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.